1, Sichuan Yu Hui Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise driven by scientific research, mainly engaged in the research, development, production and sales of anti-tumor and injectable drugs. At the same time, the company conducts business at home and abroad. In 20 14, it passed the GMP certification in Britain and China for the first time. On July 20 15, its wholly-owned subsidiary, British Sea _, obtained the qualification certification of drug release in the European Union. In the same year, the company's anti-tumor injection Irinotecan Hydrochloride Injection went on sale in the European Union. At present, the company has approved more than 10 varieties of anti-tumor injections in the UK.
2. The company has many years of research and development experience and profound technical accumulation in the field of anti-tumor injections, undertaken the research and development of four major national science and technology projects, and has a workstation for Sichuan academicians (experts), a Sichuan engineering laboratory and a postdoctoral innovation practice base; Participated in drafting the technical requirements for conformity evaluation of chemical generic drugs (injections) on the market (draft for comments), and participated in the Technical Guidance for Research and Development of Drug Injections (draft for comments), Technical Requirements for Conformity Evaluation of Quality and Efficacy of Generic Drugs for Chemical Injections, Research Guide for Compatibility of Component Systems for Chemical Injection Production (draft for comments), Technical Requirements for Sealing of Chemical Injection Packaging System (draft for comments) and so on.
3. The total number of product approvals independently approved and authorized by the company overseas exceeds 65,438+000, and currently it is mainly sold in many countries and regions such as Britain. Pemetrexed disodium for injection, docetaxel injection, azacytidine for injection, bendamustine hydrochloride for injection, paclitaxel injection, oxaliplatin injection and irinotecan hydrochloride injection have obtained domestic registration approval. In addition, at present, the products that have been registered and approved in China are Plexus for injection and palonosetron hydrochloride injection.
4. The company's registered pipeline and R&D pipeline mainly include a large number of anti-tumor injections and injection varieties with other indications, with large market capacity and high technical difficulty. It is expected to be approved earlier and enter the procurement with less competition, which will provide guarantee for the company to build a competitive threshold in the anti-tumor field, provide impetus for the company's sustained performance growth, and also provide financial guarantee for subsequent innovative drug research and development. In addition, the company has set up an innovative drug team with Dr. Haigui as the core, and the R&D pipeline includes innovative drug projects represented by biological drugs, small molecule drugs and diagnostic contrast agents in the anti-tumor field. The company regards innovative drugs as the company's long-term development strategy, forming a pattern of paying equal attention to imitation and innovation and supporting each other at home and abroad.